ReviewAntibiotics (Basel, Switzerland)2026
Natural Product-Inspired Antifungal Drugs Introduced for Human Use from 1872 to August 2026.
Review in Antibiotics (Basel, Switzerland), 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
This review provides a comprehensive account of 30 natural product (NP)-inspired antifungal therapeutic agents introduced for human use between 1872 and August 2026. These comprise 14 NPs (47%) and 16 NP-derived (NP-D; 53%) agents, the latter encompassing semisynthetic derivatives and synthetic analogues of NP scaffolds. These antifungal drugs are organised into eight structural classes, many of which share modes of action (MoA), and are individually classified as NP or NP-D, with accompanying structures illustrating the chemical modifications that link NP-D agents to their progenitor NPs. We summarise the first introduction or approval of each agent for human use by country and year, documented antifungal spectrum, routes of administration, usage status, MoA and key historical, chemical and clinical context. Analysis of the assembled dataset documents the historical importance and enduring clinical impact of these agents, while also revealing a recent concentration of approvals among NP-D inhibitors of β-1,3-D-glucan synthase. These findings underscore the enduring value of NPs as antifungal leads and highlight the need for greater chemical and mechanistic diversity in antifungal discovery, particularly through agents directed at new fungal targets.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.